Valiant Labs receives ₹12.53 Cr GST demand notice for IPO expenses, turnover mismatch
Valiant Laboratories Limited received a Show-Cause Notice from CGST & Central Excise demanding ₹12.53 Crores. This includes ₹2.85 Cr for ineligible ITC on IPO expenses, ₹9.31 Cr for turnover mismatch, and ₹36 Lakhs for GST on a corporate guarantee. Applicable interest and penalties are also proposed.
A demand of ₹12.53 Crores plus interest and penalties could impact the company's financial performance and cash flow, although it is not immediately catastrophic.
The company has received a significant GST demand notice, which poses a financial risk and potential litigation.
Valiant Laboratories Limited has received a Show-Cause Notice dated January 14, 2026, from the Office of the Commissioner of CGST & Central Excise (Audit), Raigad, Vashi, Navi Mumbai.
The notice, received via email on Wednesday, January 14, 2026, at 15:52 IST, pertains to alleged issues under the CGST Act, 2017, and SGST Act, 2017.
The primary disputes include: ineligible Input Tax Credit (ITC) on IPO expenses amounting to approximately ₹2.85 Crore, a turnover mismatch of approximately ₹9.31 Crore for FY 2021-22 due to a discrepancy between financial statements and GSTR-3B returns during the transition from partnership firm 'Bharat Chemicals' to 'Valiant Laboratories Ltd', and alleged non-payment of GST on a Corporate Bank Guarantee of ₹100 Crore provided to a related party, M/s. Valiant Advanced Services Pvt Ltd, valued at 2% per annum, resulting in a demand of approximately ₹36 Lakhs.
The Show-Cause Notice proposes a total GST demand of approximately ₹12,53,22,846 (₹12.53 Crores), along with applicable interest and penalties under Sections 50, 74, and 122 of the CGST Act, 2017.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.